VEGF 165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo
- 1 December 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 77 (6) , 1077-1086
- https://doi.org/10.1161/01.res.77.6.1077
Abstract
To evaluate the concept that localized delivery of angiogenic factors via virus-mediated gene transfer may be useful in the treatment of ischemic disorders, the replication-deficient adenovirus (Ad) vector AdCMV.VEGF 165 (where CMV is cytomegalovirus and VEGF is vascular endothelial growth factor) containing the cDNA for human VEGF 165 , a secreted endothelial cell–specific angiogenic growth factor, was constructed. Human umbilical vein endothelial cells (HUVECs) and rat aorta smooth muscle cells (RASMCs) infected with AdCMV.VEGF 165 (5 and 20 plaque-forming units [pfu] per cell) demonstrated VEGF mRNA expression and protein secretion into the supernatant. Furthermore, the conditioned medium from these cells enhanced vascular permeability in vivo. In contrast, neither VEGF mRNA nor secreted protein was found in uninfected HUVECs or RASMCs or in cells infected with the control vector AdCMV.βgal (where βgal is β-galactosidase). Assessment of starved HUVECs at 14 days demonstrated sixfold more cells for AdCMV.VEGF 165 -infected HUVECs (20 pfu per cell) than for either infected or uninfected control cells. RASMC proliferation was unaffected by infection with AdCMV.VEGF 165 . When plated in 2% serum on dishes precoated with reconstituted basement membrane (Matrigel), HUVECs infected with AdCMV.VEGF 165 (20 pfu per cell) differentiated into capillary-like structures. Under similar conditions, both uninfected HUVECs and HUVECs infected with AdCMV.βgal did not differentiate. To evaluate the ability of AdCMV.VEGF 165 to function in vivo, either AdCMV. VEGF 165 or AdCMV.βgal (2×10 10 pfu) was resuspended in 0.5 mL Matrigel and injected subcutaneously into mice. Immunohistochemical staining demonstrated VEGF in the tissues surrounding the Matrigel plugs containing AdCMV.VEGF 165 up to 3 weeks after injection, whereas no VEGF was found in the control plugs with AdCMV.βgal. Two weeks after injection, there was histological evidence of neovascularization in the tissues surrounding the Matrigel containing AdCMV.VEGF 165 , whereas no significant angiogenesis was observed in response to AdCMV.βgal. Furthermore, the Matrigel plugs with AdCMV.VEGF 165 demonstrated hemoglobin content fourfold higher than the plugs with AdCMV.βgal. Together, these in vitro and in vivo studies are consistent with the concept that Ad vectors may provide a useful strategy for efficient local delivery of VEGF 165 in the treatment of ischemic diseases.Keywords
This publication has 32 references indexed in Scilit:
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994
- Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.Journal of Clinical Investigation, 1994
- An Association between Collateral Blood Flow and Myocardial Viability in Patients with Recent Myocardial InfarctionNew England Journal of Medicine, 1992
- Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature, 1992
- Widespread long-term gene transfer to mouse skeletal muscles and heart.Journal of Clinical Investigation, 1992
- In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epitheliumCell, 1992
- Regulators of AngiogenesisAnnual Review of Physiology, 1991
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures.The Journal of cell biology, 1988
- Analysis of angiotensin‐stimulated sodium transport in cultured smooth muscle cells from rat aortaJournal of Cellular Physiology, 1983